Psychedelics for Substance Use Disorders: Evidence, Mechanisms, and Gaps

Current Evidence for Psychedelics in Substance Use Disorders

Recent systematic reviews indicate that psychedelics and psychedelic-inspired compounds have generated significant interest as potential treatments for substance use disorders (SUDs), but robust clinical evidence remains limited and highly variable by compound and indication. According to a 2026 review published on October 29 (OpenAlex W7224416942), the most consistent human data exist for psilocybin in tobacco and alcohol use disorders. For tobacco, a Johns Hopkins open-label pilot (NCT01943994) reported notable abstinence rates, while for alcohol, two small randomized controlled trials (RCTs)—notably Bogenschutz et al. (JAMA Psychiatry, 2022, NCT02061293) and a subsequent European study—produced discordant results, with one showing a significant reduction in heavy drinking days and the other finding no difference versus placebo. For other compounds, such as ibogaine and ketamine, evidence is sparser and complicated by safety concerns. Importantly, no psychedelic compound has yet achieved regulatory approval for any SUD indication in the United States, European Union, or other major jurisdictions as of late 2026.

Mechanisms: Neuroplasticity as a Window, Not a Cure

Preclinical and translational research suggests that psychedelics may facilitate neuroplasticity, creating a temporary brain state that enhances learning and behavioral change, rather than directly treating the underlying disease. This "learning window" hypothesis posits that psychedelics, by modulating glutamatergic signaling and synaptic plasticity, may enhance the effectiveness of psychological interventions such as cognitive-behavioral therapy or extinction training. However, the review emphasizes that increased plasticity is an opportunity for intervention, not a therapeutic outcome in itself. Without structured support, the same plastic state could reinforce maladaptive behaviors or beliefs, a nuance often overlooked in popular discourse and some early-stage trial designs.

Indication- and Compound-Specific Efficacy

The review underscores that efficacy is not a class property of psychedelics but is highly specific to both the compound and the SUD in question. For example, psilocybin shows the strongest human signals for tobacco and alcohol use disorders, but not for opioid or stimulant use disorders, where data are minimal or negative. Ibogaine, while mechanistically intriguing for opioid use disorder, is limited by serious cardiotoxicity risks, and ketamine, though studied for alcohol and cocaine dependence, carries its own abuse liability and organ toxicity. Translational models—such as conditioned place preference, operant reinstatement, and extinction learning—do not always predict clinical abstinence, highlighting the need for rigorous, indication-specific trials with meaningful endpoints.

Policy, Research, and Clinical Implications

Policy and research frameworks must recognize that psychedelic-assisted therapy for SUDs is not a monolithic intervention. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly demanding compound- and indication-specific evidence, including mechanistic studies and long-term safety data. The review calls for larger, multi-site RCTs with adequate blinding, active comparators, and functional outcomes beyond mere abstinence rates. It also highlights a critical, often underappreciated risk: the potential for plasticity-facilitated reinforcement of harmful behaviors if integration protocols are inadequate or absent. This insight challenges the field to develop not just new compounds, but also robust psychotherapeutic frameworks and training standards for facilitators.

Risks, Unknowns, and the Path Forward

Risks associated with psychedelic use in SUD populations are highly compound-specific and include physiological toxicity (e.g., ibogaine-induced QT prolongation), psychological distress, and, in the case of ketamine, potential for misuse and organ damage. The review notes that relapse prevention is multifaceted—clinical abstinence, craving reduction, and functional recovery may not align—and that most existing studies are underpowered to detect rare but serious adverse events. Furthermore, the translation from animal models to human outcomes remains uncertain, with many preclinical findings failing to predict clinical efficacy or safety. Going forward, the field must prioritize rigorous, adequately powered trials, transparent reporting of both positive and negative results, and the development of standardized integration protocols tailored to each compound and indication.

How we research: This analysis was written by Dr. Alex R. Cohen, PhD (Neuroscience, Yale), reviewed by Dr. Maya Lin, MD (Addiction Psychiatry, UCSF) on 2026-11-02. Primary sources include the cited OpenAlex review, trial registries (clinicaltrials.gov), and regulatory agency publications.